GlassScriptPhysician profile
Bradley Shane Taylor
NPI 1922529080
$6,732.71
in general payments reported to CMS, 2019-2025
21 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,301 · 2022: $1,516 · 2023: $1,000 · 2024: $1,521 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,915.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,915.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,914.11 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Vanta Adaptivestim |
| Boston Scientific Corporation | $1,252.82 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Collegium Pharmaceutical, INC. | $1,021.84 | 2021-2025 | Belbuca, Xtampza |
| Abbott Laboratories | $598.37 | 2021-2023 | Proclaim |
| Si-Bone, INC. | $453.25 | 2022-2025 | |
| Abbvie INC. | $418.19 | 2021-2025 | |
| Amgen INC. | $345.13 | 2021-2025 | Evenity, Prolia |
| Biohaven Pharmaceutical Holding Company LTD. | $161.09 | 2022 | |
| Scilex Pharmaceuticals INC. | $111.74 | 2021-2023 | Ztlido |
| Pfizer INC. | $95.54 | 2021-2023 | |
| Horizon Therapeutics Plc | $86.67 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $43.92 | 2022-2023 | |
| Biodelivery Sciences International, INC. | $43.23 | 2021 | |
| Spinal Simplicity, LLC | $32.90 | 2022-2023 | Ha Minuteman G3-R |
| Averitas Pharma INC. | $31.14 | 2025 | Qutenza |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $27.71 | 2021 | |
| Lilly USA, LLC | $24.48 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $21.32 | 2025 | |
| Axsome Therapeutics, INC. | $20.55 | 2025 | Symbravo |
| Ibsa Pharma INC. | $15.65 | 2023 | Tirosint, Licart |
| Kowa Pharmaceuticals America, INC. | $13.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.